Business Context and Reporting Period
Company: iBio, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: October 28, 2019 (Event Date: October 25, 2019)
Context: The Company entered into a material definitive underwriting agreement with A.G.P./Alliance Global Partners for a public offering of common stock, Series C Convertible Preferred Stock, and warrants.
Key Financial Metrics and Offering Details
This filing details a capital raise rather than operational financial results. Key metrics include:
- Securities Issued:
- 2,450,000 shares of Common Stock.
- 4,510 shares of Series C Convertible Preferred Stock (convertible at $0.20/share).
- 25,000,000 Series A Warrants (2-year expiry).
- 25,000,000 Series B Warrants (7-year expiry).
- Offering Prices:
- Common Stock + Warrants: $0.20 per share.
- Series C Preferred + Warrants: $1,000 per share.
- Warrant Exercise Price: $0.22 per share (110% of public offering price).
- Net Proceeds:
- Base Case: Approximately $4.47 million.
- With Full Over-Allotment: Approximately $5.16 million.
- Underwriting Compensation:
- Discount: 7% for new investors; 3.5% for pre-existing investors.
- Additional Compensation: 2% of aggregate shares issued to the Underwriter.
Material Changes and Structural Terms
The filing outlines significant structural terms affecting future equity and liquidity:
- Over-Allotment Option: The Underwriter holds a 45-day option to purchase up to 3,750,000 additional shares of Common Stock and/or warrants.
- Anti-Dilution Provisions:
- Preferred Stock: Conversion price adjusts downward if the Company issues stock below the conversion price, with a floor of $0.05.
- Warrants: Exercise price adjusts downward if the Company issues stock below the exercise price.
- Ownership Caps: Beneficial ownership is limited to 4.99% (or 9.99% upon election) for both Preferred Stock conversion and Warrant exercise.
- Lock-Up Agreements:
- Company, officers, directors, and key shareholders are restricted from selling stock for 90 days.
- Investors purchasing $50,000+ entered "Leak-Out Agreements" restricting sales to 35% of daily trading volume for 35 days or until 25 million shares trade.
- Right of First Refusal: The Underwriter has a 12-month right of first refusal for future equity or debt offerings.
Outlook, Risks, and Management Commentary
- Closing Date: Expected on or about October 29, 2019.
- Registration: Securities are offered pursuant to an effective Form S-1 (File No. 333-233504).
- Risks: The offering includes significant dilution risks due to the warrant structure and anti-dilution adjustments. The "Leak-Out" restrictions may limit immediate liquidity for large investors.
- Unusual Items: The inclusion of a "Leak-Out Agreement" is a specific mechanism to control secondary market selling pressure immediately following the offering.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received.
- Confirm the filing of the Series C Certificate of Designation with the Delaware Secretary of State.
- Monitor the exercise of the 45-day over-allotment option by the Underwriter.
- Review the impact of the 90-day lock-up and 35-day leak-out restrictions on trading volume and share price.
- Assess the potential dilution impact of the 50 million warrants issued at a $0.22 exercise price.